Wells Fargo
SPRY icon

Wells Fargo’s ARS Pharmaceuticals SPRY Stock Holding History

Wells Fargo’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$505K Buy
62,995
+32,610
+107% +$281K ﹤0.01% 4619
2026
Q1 		$244K Sell
30,385
-43,871
-59% -$420K ﹤0.01% 4591
2025
Q4 		$865K Buy
74,256
+414
+0.6% +$4.03K ﹤0.01% 4083
2025
Q3 		$742K Buy
73,842
+12,736
+21% +$183K ﹤0.01% 4018
2025
Q2 		$1.07M Buy
61,106
+1,459
+2% +$21.1K ﹤0.01% 3653
2025
Q1 		$750K Buy
59,647
+17,946
+43% +$216K ﹤0.01% 3839
2024
Q4 		$440K Buy
41,701
+13,361
+47% +$187K ﹤0.01% 4264
2024
Q3 		$411K Buy
28,340
+12,584
+80% +$150K ﹤0.01% 4123
2024
Q2 		$134K Buy
15,756
+7,168
+83% +$63.6K ﹤0.01% 4770
2024
Q1 		$87.8K Buy
8,588
+1,090
+15% +$8.13K ﹤0.01% 4966
2023
Q4 		$41.1K Buy
7,498
+1,562
+26% +$6.84K ﹤0.01% 5345
2023
Q3 		$22.4K Sell
5,936
-3,574
-38% -$23.5K ﹤0.01% 5551
2023
Q2 		$63.7K Buy
9,510
+9,266
+3,798% +$61.8K ﹤0.01% 5303
2023
Q1 		$1.59K Buy
244
+8
+3% +$61 ﹤0.01% 6265
2022
Q4 		$2.01K Buy
236
+84
+55% +$545 ﹤0.01% 6013
2022
Q3 		$1K Buy
152
+4
+3% +$20 ﹤0.01% 6461
2022
Q2 		$1K Sell
148
-4,045
-96% -$14.1K ﹤0.01% 6596
2022
Q1 		$14K Sell
4,193
-4,339
-51% -$18.9K ﹤0.01% 6156
2021
Q4 		$57K Sell
8,532
-8,379
-50% -$68.1K ﹤0.01% 5913
2021
Q3 		$169K Buy
16,911
+16,323
+2,776% +$403K ﹤0.01% 5175
2021
Q2 		$18K Sell
588
-3,794
-87% -$122K ﹤0.01% 5946
2021
Q1 		$191K Buy
+4,382
New +$207K ﹤0.01% 5177

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wells Fargo's SPRY Position: Q2 2026 in Review

Wells Fargo increased its ARS Pharmaceuticals (SPRY) stake by 107% in Q2 2026, buying an estimated $281K and bringing the position to 62,995 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #4619.

Wells Fargo first reported a position in SPRY in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.07M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Wells Fargo held 62,995 shares of ARS Pharmaceuticals worth $505K as of Q2 2026.
  • Wells Fargo bought 32,610 ARS Pharmaceuticals shares in Q2 2026, an estimated $281K.
  • ARS Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4619 holding.
  • Wells Fargo first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Wells Fargo's ARS Pharmaceuticals position peaked at $1.07M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.